Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

See Locations Near You

Summary

This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not previously been treated with systemic chemotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion criteria:

Patients with histologically or cytologically confirmed diagnosis of extensive disease small-cell lung cancer (ED SCLC)
Age ≥ 18 years
WHO Performance Status Grade ≤ 1 (ie. ability to perform normal daily functions)
Adequate bone marrow, liver and renal function

Exclusion criteria:

Chronic steroid treatment
Prior treatment with chemotherapy for advanced lung cancer
Prior treatment with mTOR inhibitors
Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections or other severe medical conditions
Symptomatic or uncontrolled brain metastases
Other cancers within the past 5 years
Pregnant or breastfeeding women

Other protocol-defined inclusion/exclusion criteria may apply.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT00466466

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Highlands Oncology Group
Fayetteville Arkansas, 72703, United States
University of Colorado Health Sciences Center
Aurora Colorado, 80045, United States
Dana Faber Cancer Institute
Boston Massachusetts, 02115, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Cancer Therapy and Research Center at UTHSCSA
San Antonio Texas, 78229, United States
Novartis Investigative Site
Paris , , France
Load More

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT00466466

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider